semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Asthma Clinical diagnosis of asthma according to the WHO/GINA 2006 definition by the physicians of the Centre, backed up by detailed medical history and physical examination as well as additional spirometry and bronchodilatation test or methacholine challenge where necessary Occurrence of an index event (intervention) defined as the first prescription for salmeterol or montelukast, establishing a 12-month pre-index and three consecutive 12-month post-index periods At least one inhaled glucocorticosteroid prescription in the pre-index period, and at least one salmeterol/montelukast prescription depending on the arm in every post-index period  Incomplete diagnostics
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 5.0-90.0,  Asthma Provider diagnosis of asthma (ICD9 493.xx) At least one healthcare utilization event in CHW within last 12 months; and Prescription for Short Acting Beta Agonist (SABA) at study intake  Subject is under the age of 5 at the beginning of the study Subject does not speak either English or Spanish Subject does not have access to the Internet or email to receive reports; and Subject has substantial co-morbidity (provider diagnosis of COPD
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Asthma Male or female non-smokers, aged between 18 and 65 years Clinical diagnosis of mild to moderate asthma meeting NHLBI 2007 guidelines as outlined in Appendix A Subjects who have a currently prescribed inhaled corticosteroid medication to treat asthma, alone or in combination with other medications, with usage of 1 month (≥ 95% compliance) or more on the inhaled corticosteroid treatment Normal 12-lead ECG at Screening Normal single view chest x-ray at Screening Men and women of reproductive potential who commit to use adequate contraception during the study and for 1 month following the last day of treatment (Day 57) Women of childbearing potential who have a negative pregnancy test (serum HCG) at the time of study entry, and again on Day 22 Subjects, or their legal guardians, must be capable of understanding the purpose and risks of the study and provide written, voluntary, informed consent  Chronic or acute disease that might interfere with the evaluation of RNS60 Pregnancy, intent to become pregnant, or breastfeeding Current or prior malignancies (excluding non-melanoma skin carcinoma or in situ carcinoma of the cervix that has been adequately treated) Positive viral serology test for Human Immunodeficiency Virus (HIV-1), HBsAG and Hepatitis C antibody Positive urine drug screen (UDS) for drugs of abuse including alcohol and cotinine at the time of study entry and again on Day 22 Infections that require intravenous antibiotic therapy Significant organ dysfunction, including cardiac, renal, liver, central nervous system, pulmonary, vascular, gastrointestinal, endocrine, or metabolic (e.g., creatinine ≥ 1.6 mg/dL; ALT or AST ≥ 1.5x the upper limit of normal), history of myocardial infarction, congestive heart failure, or arrhythmias within 6 months prior to study entry Treatment with a humanized or chimeric antibody therapy within 4 weeks prior to study entry Treatment with any investigational drugs, therapies, or medical devices within 4 weeks prior to study entry Any use of antidepressants or other psychiatric medicine within 4 weeks prior to study entry and/or during the study treatment period
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-17.0,  Asthma Age ≥ 12 and ≤ 17 years Mild to severe persistent asthma or poorly controlled asthma. If a child has used a preventive medication in the past, but reports no use of the medication in the prior 3 months, we will assess severity Children not using a preventive medication at baseline: We will assess for mild persistent to severe persistent asthma. Any one of the following, during the prior 4 weeks (as defined by parent interview) will determine severity An average of >2 days per week with asthma symptoms >2 days per week with rescue medication use ≥2 nights per month awakened with nighttime symptoms Minor limitation of activity ≥2 episodes of asthma during the past year that have required systemic corticosteroids Children using a preventive medication at baseline: We will assess for poorly controlled asthma. Any 1 of the following, during the prior 4 weeks (as defined by parent interview in the waiting room) will determine control An average of >2 days per week with asthma symptoms  Significant underlying respiratory disease other than asthma (such as cystic fibrosis or chronic lung disease) that could potentially interfere with asthma-related outcome measures Significant co-morbid conditions (such as moderate to severe developmental delay, i.e. special education classroom or diagnosis) that could preclude participation in an education-based intervention Inability to speak or understand English (child or parent) Children in foster care or other situations in which consent cannot be obtained from a guardian Prior enrollment in the study
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 7.0-18.0,  Asthma Patients age ≥ seven years Previous diagnosis of asthma or previous episode of wheezing treated with beta-agonist medication Able to complete bedside spirometry FEV1 < 70% predicted  Known allergy to magnesium sulfate Known contra-indication to albuterol Respiratory distress occurring as a result of bedside spirometry History of neuromuscular disease, cardiac disease, renal disease, or underlying chronic lung disease Pregnancy Use of oral steroid medication within 72 hours of presentation Radiographic evidence of pneumonia at presentation Intubation during the current encounter prior to study enrollment Administration of intravenous magnesium sulfate prior to study enrollment Prior participation in this study
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Asthma Viral Infection Age between 18 years History of episodic chest tightness and wheezing Intermittent or mild persistent asthma according to the by the Global Initiative for Asthma Non-smoking or stopped smoking more than 12 months ago and ≤ 5 pack years (PY) Clinically stable, no history of exacerbations within the last 6 weeks prior to the study Steroid-naïve or those patients who are currently not on corticosteroids and have not taken any corticosteroids by any dosing-routes within 2 weeks prior to the study. Occasional usage of inhaled short-acting beta2-agonists as rescue medication is allowed, prior and during the study Baseline FEV1 > 80% of predicted Airway hyperresponsiveness, indicated by a positive acetyl-ß-methylcholine bromide (MeBr) challenge with PC20 < 9.8 mg/ml Positive skin prick test (SPT) to one or more of the 12 common aeroallergen extracts, defined as a wheal with an average diameter of > 3mm  Presence of antibodies directed against RV16 in serum (titer > 4), measured at visit 1 History of clinical significant hypotensive episodes or symptoms of fainting, dizziness, or light-headedness Women who are pregnant, lactating or who have a positive urine pregnancy test at visit 1 Chronic use of any other medication for treatment of lung disease other than short-acting beta2-agonists Participation in any clinical investigational drug treatment protocol within the preceding 3 months Ongoing use of tobacco products of any kind or previous usage with ≥ 6 total PY Concomitant disease or condition which could interfere with the conduct of the study, or for which the treatment might interfere with the conduct of the study, or which would, in the opinion of the investigator, pose an unacceptable risk to the patient People with young children (< 2 years)
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 2.0-12.0,  Status Asthmaticus Children 2-12 years of age with physician diagnosed asthma or a previous episode of SOB that responded well to β2-agonists who present to the ER with moderate or severe asthma exacerbation  Children with mild asthma exacerbation Children with severe asthma exacerbation who are in critical condition or need immediate intervention Children who have heart disease or chronic lung disease other than asthma Systemic steroids administered within the past 7 days
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 6.0-14.0,  Asthma Children with physician diagnosed asthma aged 6 years -14 years, 11months Those requiring frequent short-acting beta2 agonist relief therapy ≥ 7 puffs in the past seven days Those with symptoms of asthma (i.e. wheeze, shortness of breath but not cough alone) resulting in: i. Nocturnal wakening in the last week because of asthma symptoms and/or ii. Asthma has interfered with usual activities in the last week and/or iii. Those who have had exacerbations, defined as a short course of oral corticosteroids, an unscheduled GP or A&E Department visit or a hospital admission within the previous 6 months Fully informed written (proxy) consent and assent, where appropriate  Children receiving long acting beta2-agonists, leukotriene receptor antagonists, regular theophylline therapy or high dose ICS >1000micrograms and unlicensed beclometasone dipropionate or equivalent (at the discretion of the investigator) Children with other respiratory diseases, cystic fibrosis, cardiac disease or immunological disorders Non-English speaking
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 16.0-80.0,  Asthma This pilot study will investigate the following groups (n=10 per group): 1. Healthy volunteers. 2. Steroid naïve asthmatics. 3. Refractory asthmatics adherent to high dose inhaled steroids. 4. Non-adherent asthmatics. For into this study all participants must be 16 years old or older give written informed consent Healthy volunteers must be in good general health as determined by past medical history and physical have no other significant medical history and specifically no prior history of asthma or persistent respiratory symptoms normal spirometry. Steroid naïve subjects have a diagnosis of asthma receiving treatment at Step 1 BTS/SIGN Guidelines i.e. no inhaled steroid Non-adherent subjects must have a diagnosis of asthma be non-adherent to ICS as determined by ICS prescription filling of </=50% in the previous 6 months Refractory asthmatic adherent subjects must  Participants who fulfill the following will be excluded from study entry Current smoker Pregnant or lactating Other significant respiratory disease Previous allergic reaction or known hypersensitivity to budesonide or any corticosteroid Healthy volunteers will be excluded if they have / are  any significant medical history which the principal investigator (PI) deems appropriate to be excluded from the healthy control group obstructive lung function taking any medication a current or history of drug or alcohol abuse any significant illness during the screening period preceding entry into the study Steroid naïve / Non-adherent asthmatics will be excluded if they have
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-95.0,  Respiratory; Complications, Therapy Bronchiectasis All subjects ≥ 18 years old Diagnosis of bronchiectasis using a high-resolution computed tomography (HRCT) chest scan performed in the last 2 years Clinically stable disease (defined as no requirement for antibiotics for exacerbation in the 4 weeks preceding study entry Chronic sputum expectoration >10ml/24h  Bronchiectasis secondary to cystic fibrosis Inability to perform physiotherapy techniques Inability to attend the following controls Treatment with mucolytics, DNase or hypertonic saline during the study Smokers and ex-smokers ≥ 10 pack/year
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-17.0,  Asthma Age 12-17 years (inclusive) Weight greater than (>) 30 kilogram (kg) Asthma for a minimum of 6 months prior to Screening Effective birth control for both male and female participants in line with protocol details  Previously taken tralokinumab (the study drug) Employee of the clinical study site or any other individuals directly involved with the conduct of the study, or immediate family members of such individuals Pregnant or breastfeeding women Current smoker or cessation less than (<) 3 months prior to screening Known immune deficiency excluding asymptomatic selective immunoglobulin A History of cancer Hepatitis B, C or human immunodeficiency virus (HIV) positive Any disease which may cause complications whilst taking the study drug
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 6.0-999.0,  Asthma Clinical history consistent with asthma in male and female subjects ages 6 and above Need for controller therapy demonstrated by current use of a stable dose (at least 4 weeks) of long term asthma controller therapy; or if not receiving long term asthma controller, symptoms consistent with persistent asthma (eg. Symptoms > 3x per week) Prebronchodilator FEV1 > 40% predicted at screening (V0) Positive skin test (defined as wheal greater than 3 mm in diameter greater than saline negative control) to protein extracts of at least one of 9 common indoor allergens including dust mites, cockroach mix, rat, mouse, Alternaria, Cladosporium, Aspergillus, cat and dog tested at Visit 0 (or positive RAST test to at least on aeroallergen if FEV1<60% at Visit 0 precluding allergen skin testing.) Evidence of at least one allergen in household dust which matches skin test positivity or RAST testing (overlap to be checked and recorded at V3) Asthma confirmed by either reversibility to 4 puffs albuterol greater than or equal to 12% in FEV1 at V0 OR PC20 FEV1 methacholine of less than or equal 16 mg/ml at or up to 30 days previous to V1 Sleeps overnight at same address at least 5 times per week  Significant medical illness other than asthma including other chronic respiratory illness (eg emphysema, cystic fibrosis) Currently receiving immunotherapy or received such therapy in the past year Emergency Department (ED) visit for asthma or steroid taper within the past 2 weeks (may be rescreened at a future date) Investigational drug within the past 30 days; anti-IgE therapy within past 6 months Active smoker or greater than 10 pack year history of asthma Asthma requiring mechanical ventilation within the past 5 years Significant occupational exposures as determined by principal investigator
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 13.0-999.0,  Pertussis Adolescents aged 13-18 years or adults aged >18years Presenting with prolonged cough of 2 weeks (14 days) or more Subjects who the investigator believes that they/ their parent(s)/Legally Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of the protocol Written informed consent obtained from the subject/ from the parent(s)/LAR of the subject. If the subject below the age of consent is legally eligible, his/her signature on the informed assent form should be obtained  Child in care Subjects with known chronic cough-causing disease and immunodeficiency Subjects treated with angiotensin-converting enzyme inhibitors (ACEI), within the past 4 weeks (28 days)